Prescription drug · NDA
Avopef (Etoposide) NDC 83831-144
Etoposide 100 mg/5mL · Injection · Intravenous · AVYXA Pharma, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83831-144-05 | 8383101440583831014405 | 1 VIAL in 1 CARTON (83831-144-05) / 5 mL in 1 VIALMarketed from Apr 1, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Avopef
- Generic name (nonproprietary)
- etoposide
- Active ingredients
- Etoposide — 100 mg/5mL
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- AVYXA Pharma, LLCNDC labeler code 83831
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 220200
- Marketing start
- Listing expires
- Other FDA classes
- Topoisomerase Inhibitors (Mechanism)
- Identifiers
- Product ID 83831-144_d2f8949c-2fc5-46c5-befb-f03cbb80d59eSPL ID d2f8949c-2fc5-46c5-befb-f03cbb80d59e
- Pharmacologic class
- Topoisomerase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N483831014405followed by a unit qualifier and the quantityPackage 83831-0144-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
The FDA listing for this product does not reference a label (SPL) set.
About NDC 83831-144
- What is NDC 83831-144?
- 83831-144 is the product NDC for Avopef (etoposide), Etoposide 100 mg/5mL injection, listed with the FDA by AVYXA Pharma, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Avopef (Etoposide).
- What is the active ingredient?
- Etoposide.
- Who is the labeler?
- AVYXA Pharma, LLC, NDC labeler code 83831. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Avopef?
- 1 other product NDC are listed under this name. See all Avopef NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Avopef products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Avopefetoposide | Etoposide 500 mg/25mL | InjectionIntravenous | AVYXA Pharma, LLC | 83831-145 | 83831-0145-25 |
Other NDCs under NDA 220200
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Avopefetoposide | Etoposide 500 mg/25mL | InjectionIntravenous | AVYXA Pharma, LLC | 83831-145 |